Cyclerion Therapeutics Files Q1 2025 10-Q, Details Equity Transactions
Ticker: CYCN · Form: 10-Q · Filed: May 6, 2025 · CIK: 1755237
| Field | Detail |
|---|---|
| Company | Cyclerion Therapeutics, Inc. (CYCN) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, equity-financing, pharmaceutical
TL;DR
**Cyclerion Q1 10-Q out: Equity private placement done March 21, 2025. Watch cash burn.**
AI Summary
Cyclerion Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial activities and equity transactions, including preferred stock, additional paid-in capital, and employee stock options. Notably, the company engaged in a private placement of equity on March 21, 2025.
Why It Matters
This filing provides insight into Cyclerion's financial health and strategic equity movements during the first quarter of 2025, which could impact future operations and investor confidence.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Cyclerion faces inherent risks related to drug development, regulatory approvals, and market competition, which are not fully detailed in this summary but are typical for the industry.
Key Numbers
- N/A — Revenue (Specific revenue figures for the quarter are not detailed in the provided text.)
- N/A — Net Loss (Specific net loss figures for the quarter are not detailed in the provided text.)
- N/A — Cash and Equivalents (Specific cash balance figures for the quarter are not detailed in the provided text.)
Key Players & Entities
- Cyclerion Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- March 21, 2025 (date) — Date of equity private placement
FAQ
What was the total amount raised in the equity private placement on March 21, 2025?
The provided text mentions the 'TwoThousandTwentyFiveEquityPrivatePlacementMember' on March 21, 2025, but does not specify the dollar amount raised.
What is the current status of Cyclerion's drug pipeline as of March 31, 2025?
The provided text does not contain information regarding the status of Cyclerion's drug pipeline.
How does the company's financial position compare to the same period in the previous year?
The provided text focuses on the current period and does not offer comparative financial data for the prior year's quarter.
What are the specific terms of the Series A Convertible Preferred Stock mentioned?
The filing mentions 'SeriesaConvertiblePreferredStockMember' as of December 31, 2024, but the specific terms are not detailed in the provided excerpt.
Are there any significant changes in the company's executive leadership or board of directors reported in this 10-Q?
The provided text does not include information about changes in executive leadership or the board of directors.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Cyclerion Therapeutics, Inc. (CYCN).